JP6626449B2 - ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物 - Google Patents

ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物 Download PDF

Info

Publication number
JP6626449B2
JP6626449B2 JP2016549758A JP2016549758A JP6626449B2 JP 6626449 B2 JP6626449 B2 JP 6626449B2 JP 2016549758 A JP2016549758 A JP 2016549758A JP 2016549758 A JP2016549758 A JP 2016549758A JP 6626449 B2 JP6626449 B2 JP 6626449B2
Authority
JP
Japan
Prior art keywords
methyl
triazolo
pyrimidin
piperidine
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513808A (ja
JP2017513808A5 (pt-PT
Inventor
ジェームズ・ブレイテンブッヒャー
グレイム・フリーストーン
ローレント・ゴメス
ロバート・レムス
キエフ・レイ
マーガレット・マカリック
ウィリアム・ヴァーニャー
トロイ・ヴィッカース
Original Assignee
ダート・ニューロサイエンス・（ケイマン）・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダート・ニューロサイエンス・（ケイマン）・リミテッド filed Critical ダート・ニューロサイエンス・（ケイマン）・リミテッド
Publication of JP2017513808A publication Critical patent/JP2017513808A/ja
Publication of JP2017513808A5 publication Critical patent/JP2017513808A5/ja
Application granted granted Critical
Publication of JP6626449B2 publication Critical patent/JP6626449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016549758A 2014-04-23 2015-04-22 ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物 Active JP6626449B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983387P 2014-04-23 2014-04-23
US61/983,387 2014-04-23
PCT/US2015/027102 WO2015164508A1 (en) 2014-04-23 2015-04-22 Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors

Publications (3)

Publication Number Publication Date
JP2017513808A JP2017513808A (ja) 2017-06-01
JP2017513808A5 JP2017513808A5 (pt-PT) 2018-05-24
JP6626449B2 true JP6626449B2 (ja) 2019-12-25

Family

ID=53055118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549758A Active JP6626449B2 (ja) 2014-04-23 2015-04-22 ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物

Country Status (23)

Country Link
US (4) US9932345B2 (pt-PT)
EP (2) EP3597649B8 (pt-PT)
JP (1) JP6626449B2 (pt-PT)
KR (1) KR102471058B1 (pt-PT)
CN (2) CN106459062A (pt-PT)
AU (2) AU2015249753B2 (pt-PT)
BR (1) BR112016024713B1 (pt-PT)
CA (1) CA2938294C (pt-PT)
DK (2) DK3597649T3 (pt-PT)
ES (2) ES2902806T3 (pt-PT)
HR (1) HRP20212035T1 (pt-PT)
HU (1) HUE057317T2 (pt-PT)
IL (2) IL248292A (pt-PT)
MA (1) MA50375A (pt-PT)
MX (1) MX358004B (pt-PT)
NZ (1) NZ725161A (pt-PT)
PL (1) PL3597649T3 (pt-PT)
PT (1) PT3597649T (pt-PT)
RU (1) RU2659070C9 (pt-PT)
SG (1) SG11201606216UA (pt-PT)
SI (1) SI3597649T1 (pt-PT)
TW (1) TWI664181B (pt-PT)
WO (1) WO2015164508A1 (pt-PT)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3597649T3 (da) 2014-04-23 2022-01-10 Dart Neuroscience Llc Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
SG11201701315VA (en) 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
TWI568737B (zh) * 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
CA3001768C (en) * 2015-11-02 2022-12-13 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
KR20180132060A (ko) 2016-02-25 2018-12-11 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CA3012624A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
EA039102B1 (ru) * 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
AU2017353310B2 (en) 2016-11-02 2021-08-12 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors
MA46690A (fr) * 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
WO2018109198A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
MA47591A (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
CA3138307A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
HU208693B (en) 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
US5478825A (en) 1991-02-22 1995-12-26 Egis Gyogyszergyar 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
DK1355669T3 (da) 2000-08-10 2011-11-21 Cold Spring Harbor Lab Forbedret kognitiv træning
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
EP1597386A1 (en) 2002-11-13 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
US20070275961A1 (en) * 2003-06-04 2007-11-29 Vernalis (Cambridge) Limited. Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
AU2005279221C9 (en) 2004-09-02 2012-08-23 Takeda Gmbh Triazolophthalazines
JP5130053B2 (ja) 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
CN101103033B (zh) 2005-01-05 2010-08-04 尼科梅德有限责任公司 作为pde2抑制剂的三唑并酞嗪
US7868016B2 (en) 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
CN101321758A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 用于治疗哮喘和慢性阻塞性肺病的新5,6－二氢吡唑并[3,4－e][1,4]二氮杂－4(1H)－酮衍生物
KR100844125B1 (ko) 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
EP2152275A4 (en) 2007-05-15 2011-08-03 Helicon Therapeutics Inc METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA (SIARN)
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
WO2010054260A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
AP2011005819A0 (en) 2009-03-31 2011-08-31 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
US8680116B2 (en) 2009-07-22 2014-03-25 Merck Sharp & Dohme Corp. Quinolinone PDE2 inhibitors
ES2553610T3 (es) * 2010-12-14 2015-12-10 Electrophoretics Limited Inhibidores de la caseína cinasa 1 delta (CK1delta)
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
JP5543039B2 (ja) * 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
WO2012168817A1 (en) 2011-06-07 2012-12-13 Pfizer Inc. Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
EP3026051A4 (en) * 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3597649T3 (da) 2014-04-23 2022-01-10 Dart Neuroscience Llc Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物

Also Published As

Publication number Publication date
MA50375A (fr) 2021-05-26
US20200095256A1 (en) 2020-03-26
CA2938294A1 (en) 2015-10-29
HRP20212035T1 (hr) 2022-04-01
WO2015164508A4 (en) 2015-12-23
DK3134413T3 (da) 2019-10-14
RU2659070C9 (ru) 2018-08-24
TWI664181B (zh) 2019-07-01
IL248292A (en) 2017-09-28
JP2017513808A (ja) 2017-06-01
US20230192698A1 (en) 2023-06-22
EP3597649B8 (en) 2022-02-16
US10501465B2 (en) 2019-12-10
MX358004B (es) 2018-07-31
ES2902806T3 (es) 2022-03-29
CA2938294C (en) 2023-02-21
SI3597649T1 (sl) 2022-04-29
US20180179216A1 (en) 2018-06-28
EP3134413B1 (en) 2019-09-11
BR112016024713A2 (pt) 2017-08-15
BR112016024713B1 (pt) 2023-05-02
CN106459062A (zh) 2017-02-22
AU2019283994A1 (en) 2020-01-23
KR102471058B1 (ko) 2022-11-25
US9932345B2 (en) 2018-04-03
AU2019283994C1 (en) 2021-12-09
AU2015249753B2 (en) 2019-10-10
WO2015164508A1 (en) 2015-10-29
NZ725161A (en) 2017-10-27
TW201625625A (zh) 2016-07-16
CN110092788B (zh) 2022-02-25
IL254224B (en) 2019-01-31
AU2015249753A1 (en) 2016-11-03
CN110092788A (zh) 2019-08-06
PT3597649T (pt) 2022-01-21
IL254224A0 (en) 2017-10-31
EP3597649B1 (en) 2021-10-13
US20170057967A1 (en) 2017-03-02
MX2016013860A (es) 2017-05-12
RU2016143387A3 (pt-PT) 2018-05-23
PL3597649T3 (pl) 2022-04-04
DK3597649T3 (da) 2022-01-10
KR20160145745A (ko) 2016-12-20
EP3134413A1 (en) 2017-03-01
HUE057317T2 (hu) 2022-04-28
RU2659070C2 (ru) 2018-06-28
SG11201606216UA (en) 2016-09-29
EP3597649A1 (en) 2020-01-22
AU2019283994B2 (en) 2021-05-27
ES2759246T3 (es) 2020-05-08
RU2016143387A (ru) 2018-05-23
US11186582B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
JP6626449B2 (ja) ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
KR20200074164A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
US11618753B2 (en) Aminopyrrolotriazines as kinase inhibitors
KR102292433B1 (ko) Gsk-3 억제제로서 유용한 치환된 피리딘 유도체
TWI568737B (zh) 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
AU2010291199A1 (en) Pyrazinylpyridines useful for the treatment of proliferative diseases
US9708334B2 (en) Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
KR102590848B1 (ko) Pde2 억제제로서 치환된 피라졸로피리미디논 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161019

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191129

R150 Certificate of patent or registration of utility model

Ref document number: 6626449

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250